Compare EOG Resources Inc (EOG) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Novartis AG — how do they compare? EOG Resources Inc trades at $144 (market cap $74.60B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Novartis AG is far larger — about 4× EOG Resources Inc's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| EOG | NVS | |
|---|---|---|
Market Cap | $74.60B | $298.18B |
Sector | Energy | Health |
52-Week High | $149.89 | $168.62 |
52-Week Low | $101.78 | $118.55 |
Enterprise Value | $77.94B | $339.50B |
Dividend Yield | 2.87% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $134.74, down 1.07% with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $5.07, beating estimates, with revenue growth driven by higher oil prices and production. Valuation metrics remain attractive with P/E of 10.49 and EV/EBITDA of 5.32, while maintaining robust profitability with 25.81% net margin and 22.51% ROE.
EOG presents a compelling value opportunity with strong earnings momentum and shareholder returns through dividends. However, negative cash flow trends and energy price volatility pose near-term risks. Analyst consensus remains bullish with $162.11 price target, representing 20% upside potential from current levels.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
